Form 4: Lexicon Pharmaceuticals Executive Granted Stock Options and Restricted Stock Units

Craig B. Granowitz, SVP and Chief Medical Officer of Lexicon Pharmaceuticals, received stock options and restricted stock units on February 13, 2025.

Summary

• Craig B. Granowitz, SVP, Chief Medical Officer of Lexicon Pharmaceuticals, filed a Form 4 on February 18, 2025.
• The filing reports the grant of stock options and restricted stock units on February 13, 2025.
• Granowitz received options to purchase 910,170 shares of common stock at an exercise price of $0.695.
• These options vest over time, starting with 25% on the first anniversary of the grant date, and then 1/48th per month thereafter.
• He also received 606,780 restricted stock units, which represent a contingent right to receive one share of common stock each.
• These restricted stock units vest in three equal installments on February 28 of each of the three years following the year of grant.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation. It is neither particularly positive nor negative, but reflects standard corporate practice.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include a mix of salary, bonus, stock options, and restricted stock units.
• The specific amounts and vesting schedules vary depending on the company's size, performance, and the executive's role.
• Comparing Lexicon Pharmaceuticals' executive compensation to that of similar-sized biotech companies would provide a better understanding of its competitiveness.

Stakeholder Impact

• Shareholders may view the grant of equity compensation as a positive sign, aligning management's interests with their own.
• Employees may be motivated by the knowledge that executives are incentivized to improve company performance.

Key Dates